Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Acta Otolaryngol ; 142(6): 515-519, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1895630

ABSTRACT

BACKGROUND: One of the most common symptoms in COVID-19 patients is olfactory and taste dysfunction. AIMS/OBJECTIVES: This study aimed to evaluate the olfactory threshold, and identification using objective tests in the Iranian population. MATERIAL AND METHODS: The present study was a prospective cohort study conducted in 2020-2021 on clinically recovering COVID-19 patients. Olfactory function was evaluated at the baseline, 4-6 weeks, and 12 weeks later. Olfactory threshold assessment was performed using the Saba Sabalan kit. The Iranian version of the Pennsylvania Smell Identification Test (IR-SIT) was used for olfactory identification. The olfactory threshold was categorized as poor (<8) and good olfaction (≥8). RESULTS: In the present study, 111 patients were examined, including 55 men and 56 women (mean age 41.4 and 53.4 years, respectively). The mean olfactory threshold was better for men (7.2) than for women (6.6). Analysis showed age to have a negative relationship with good olfaction at baseline (OR = 0.93, p = .05). Using IR-SIT, only 29.7% had normal olfactory function. Using linear regression, smoking was found to be significantly related to baseline IR-SIT score (adjusted Beta <0.001, p = .03). CONCLUSIONS AND SIGNIFICANCE: Objective tests are appropriate methods for assessing olfactory dysfunction in COVID-19 patients. Further studies are recommended.


Subject(s)
COVID-19 , Olfaction Disorders , Adult , COVID-19/epidemiology , Female , Humans , Iran/epidemiology , Male , Middle Aged , Olfaction Disorders/diagnosis , Olfaction Disorders/epidemiology , Olfaction Disorders/etiology , Prospective Studies , SARS-CoV-2 , Smell
2.
Transpl Infect Dis ; 22(6): e13420, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-650852

ABSTRACT

BACKGROUND: In late December 2019, a novel coronavirus SARS-CoV-2 started to spread around the world in different populations. Its clinical and laboratory characteristics and outcome in kidney transplant recipients are little known. Therefore, we describe 22 kidney transplant recipients with SARS-CoV-2-induced pneumonia. METHODS: All kidney transplant recipients who referred to the Razi Hospital of Rasht with a diagnosis of SARS-CoV-2 infection from February 20 to 19th of April 2020 have been included in this observational study. RESULTS: We present 22 cases of COVID-19 in kidney transplant recipients (median age 52 years [interquartile range 40.75-62.75 years]) and baseline eGFR 60 (mL/min/1.73 m2 ) (44.75-86.75). Patients complained of cough (72.7%), dyspnea (63.6%), fever (68.2%), and chill (72.7%) with greater prevalence. We decreased the dose of immunosuppression and started stress dose of intravenous hydrocortisone or equivalent oral prednisolone. Each patient received antiviral therapy based on the latest updated version of local protocol at the time of admission. CT scan findings in 90.9% of patients showed bilateral multifocal lesions. Acute kidney injury (AKI) was observed in 12 patients during hospitalization. Six patients died after a median of 12 days from admission (IQR, 1-21). CONCLUSIONS: In this small observational study, we observed high AKI occurrence and mortality rate in kidney transplant recipients with COVID-19.


Subject(s)
Acute Kidney Injury/complications , COVID-19/diagnosis , Kidney Transplantation , Transplant Recipients , Adult , COVID-19/complications , COVID-19/mortality , Chills/etiology , Cough/etiology , Dyspnea/etiology , Female , Fever/etiology , Hospitalization , Hospitals , Humans , Hydrocortisone/administration & dosage , Immunocompromised Host/drug effects , Immunosuppression Therapy , Immunosuppressive Agents/administration & dosage , Iran , Male , Middle Aged , Prednisolone/administration & dosage , SARS-CoV-2/isolation & purification , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL